EWA
JSPR icon

EverSource Wealth Advisors’s Jasper Therapeutics JSPR Stock Holding History

EverSource Wealth Advisors’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-65
Closed -$361 – 4409
2025
Q2 		$361 Buy
+65
New +$320 ﹤0.01% 3967

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

EverSource Wealth Advisors's JSPR Position: Q3 2025 in Review

EverSource Wealth Advisors sold out of Jasper Therapeutics (JSPR) in Q3 2025, closing a stake of 65 shares — an estimated $361 sold.

EverSource Wealth Advisors first reported a position in JSPR in Q2 2025 and held it in 1 quarter. The position peaked at $361 in Q2 2025. 60 funds tracked by Wall St. Rank hold JSPR as of Q3 2025.

  • EverSource Wealth Advisors reported no remaining Jasper Therapeutics position as of Q3 2025 after selling out during the quarter.
  • EverSource Wealth Advisors sold 65 Jasper Therapeutics shares in Q3 2025, an estimated $361.
  • EverSource Wealth Advisors first reported a position in Jasper Therapeutics in Q2 2025 and held it in 1 quarter.
  • EverSource Wealth Advisors's Jasper Therapeutics position peaked at $361 in Q2 2025.
  • 60 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q3 2025.

Based on EverSource Wealth Advisors's 13F filing for Q3 2025, filed 10 Nov 2025.